Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vaxart, Inc.

Get SEC filing alerts via email and in your feed for Vaxart, Inc.

VXRT

Vaxart, Inc.

About Vaxart, Inc.

Vaxart, Inc. is a biotechnology company specializing in oral recombinant vaccines using its proprietary VAAST platform. It develops vaccines for infectious diseases like norovirus, COVID-19, influenza, and HPV, emphasizing ease of administration and mucosal immunity. The company focuses on clinical-stage vaccine candidates, leveraging innovative delivery methods, patent protection, and strategic partnerships to address unmet medical needs globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vaxart, Inc.

1
1
Vaxart, Inc. Vaxart Reports 88% Revenue Growth and Net Income Turnaround in Latest Quarterly Filing

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Vaxart, Inc. Vaxart Reports $16.3 Million Net Income for 2025, Driven by $237.3 Million Revenue

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Vaxart, Inc. Vaxart Reports $72.4 Million Revenue in Q3 2025, Enters Collaboration with Dynavax

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vaxart, Inc. Vaxart Reports 521% Revenue Growth in Q2 2025 Amid Rising Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vaxart, Inc. Vaxart Reports 857% Revenue Growth to $20.9 Million, Despite Net Loss of $15.6 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vaxart, Inc. Vaxart Reports $66.9 Million Net Loss and $28.7 Million Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Vaxart, Inc. Vaxart Reports Revenue Growth and Improved Operating Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments